DAZZEON Biotech is pleased to announce the signing of a collaborative intent agreement with the renowned Utrecht University, Netherlands, this March 2024. This alliance signifies a new chapter in academia-industry collaboration, focusing on the preclinical animal trials of our proprietary component, aloe polysaccharides, for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
The joint project will harness Utrecht University’s academic excellence and leading-edge research on respiratory disease models, aiming to identify the most effective polysaccharide composition for COPD. This venture is not just a step toward enhancing the therapeutic potential of aloe polysaccharides in respiratory ailments but also sets the stage for future pharmaceutical developments targeting mucosal diseases of the respiratory tract.
Utrecht University’s prominent position in the field of respiratory disease models in the Netherlands and Europe lends significant credibility to this partnership. DAZZEON Biotech looks forward to working with Utrecht University to spearhead breakthroughs in medical research, offering new treatment hopes to patients with chronic respiratory conditions.